Contribute Try STAT+ Today

SAN FRANCISCO — Moderna Therapeutics had record-setting success raising money from private investors, but the much-discussed biotech has struggled to convince the public markets of its industry-upending potential, and its stock price has slumped nearly 30 percent in the weeks following what was biotech’s largest-ever initial public offering.

That left Moderna CEO Stéphane Bancel, speaking before a standing-room crowd at the industry’s premiere gathering on Tuesday, with a curious task: convincing investors that his $5 billion company is actually undervalued.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I looked at Moderna’s webpage and am scratching my head about their strategy. They give the impression that they have discovered this new stuff, called RNA, which might be impressive to non-scientists who have never heard of it, but to a scientist? It seems pretty silly to get excited about something that we all know a great deal about…

Comments are closed.